Anti-Hormone Therapy (With Anastrazole and Fulvestrant) Before Surgery to Treat Postmenopausal Women With Breast Cancer.

• Status: Active, not recruiting
• Trial end date: 2022-05-01

Summary

This study is being done to test the safety and effectiveness of two drugs, Anastrozole and Fulvestrant, used as combined therapy in the neo-adjuvant setting for hormone receptor positive invasive breast cancer.

• Phase: Phase 2

Details

• Lead Sponsor: University of Kansas Medical Center
• Collaborator: AstraZeneca
• Treatments: Anastrozole; Estradiol; Fulvestrant; Hormones